Answers are grounded in this paper and cite their sources.
INTRODUCTION: The use of tofersen, an antisense oligonucleotide against SOD1, has been recommended for the treatment of SOD1-ALS by current European guidelines. Before full approval by national health funding agencies, patients received tofersen through the Early Access Program (EAP) and/or as rescue therapy. AIM OF THE STUDY: The aim of the study was to prospectively analyze clinical outcomes and neurofilament light chain (NfL) concentration in patients participating in the EAP in Poland between October 2023 and October 2025. MATERIAL AND METHODS: Twenty patients with SOD1-ALS (11 with familial and 9 with sporadic ALS; male:female ratio, 2.2:1) were enrolled in the EAP. They carried 11 SOD1 pathological variants, the most frequent being L145S and K4E. As 1 patient withdrew after the first dose of treatment, data were collected from 19 individuals. The median age at disease onset was 49 years (33-69 years). Disease duration before treatment was 39 months (8-110 months), and the median age at initiation of tofersen treatment was 51 years (39-74 years). The analysis included demographic and genetic data, ALS functional rating scale-revised (ALSFRS- -R), ALS progression rate, forced vital capacity (FVC), adverse events, and NfL concentration in cerebrospinal fluid. RESULTS: The median duration of tofersen treatment was 16 months (7-24 months). ALSFRS-R stabilized or increased in 68% of cases. Median delta ALSFRS-R during the treatment period was 0/month. The overall median progression rate decreased significantly from 0.218/month before treatment to 0.145/month at the last assessment (p < 0.0001). The decrease was observed in all patients, including fast-progressing individuals with continuous functional decline, as well as those with the most benign disease course. Two patients developed respiratory insufficiency, while FVC did not deteriorate in the remaining subjects. NfL concentration decreased in all analyzed patients, with significant reductions after 9 and 14 months. Serious treatment-related adverse events (SAEs) occurred in 3 patients and resolved without clinical consequences in 2 individuals. Two patients died due to disease progression and/or exacerbation of a preexisting condition/SAE. CONCLUSIONS: The long-term follow-up data support the clinical efficacy and acceptable safety profile of tofersen treatment and demonstrate a biomarker response reflecting reduced axonal injury in both slow- and fast-progressing SOD1-ALS.
No takes yet. Share an insight, caveat, or question.
Kuźma‐Kozakiewicz et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: